中国恒大的股价定格在0.16港元，总市值仅约21.52亿港元。 沉寂许久的地产股迎来了难得的狂欢。8月25日，在楼市利好政策的预期下，AH股的各大地产股集体飘红。 截至收盘，A股方面，万通发展（600246.SH）涨停，万科A（000002.SZ）、深深房A（000029.SZ）涨幅超9%，荣盛发展（002146.SZ）、金地集团 （600383.SH）涨超6%，绿地控股（600606.SH）、保利发展（600048.SH）、华发股份（600325.SH）涨幅超4%。 港股方面，万科企业（02202.HK）涨幅为9.86%，融创中国（01918.HK）上涨超6%，龙湖集团（00960.HK）、新世界发展（00017.HK）升逾5%，富力地 产（02777.HK）、越秀地产（00123.HK）等涨幅均突破4%。 巅峰之后不久，恒大的泡沫旋即被戳破。2021年，恒大的流动性危机曝光，当年12月即全面开启境外债务重组。此后，由于恒大物业发现134亿元资金被占 用一事，"恒大系"上市公司开启了长达500余天的停牌。 2023年7月17日，中国恒大披露了2021和2022两个财务年度的经营数据，合计超8000亿元的天文 ...

Core Viewpoint - The pharmaceutical market, particularly innovative drug companies, is experiencing significant growth, with substantial support from policies, leading to the emergence of high-performing stocks similar to Changchun Gaoxin. Group 1: Market Performance - The Hong Kong innovative drug index has increased from 859 points at the beginning of the year to 1284 points, representing a 50% rise [1] - The mainland innovative drug index has risen from a low of 948 to a high of 1156, showing a 22% increase, indicating a significant lag compared to Hong Kong [1] Group 2: Stock Performance - Several stocks in the Hong Kong innovative drug sector have seen substantial gains, such as: - Kintor Pharmaceutical rising from 2.48 to 19.78 HKD - Akeso increasing from 1.2 to 4.3 HKD - CanSino Biologics moving from 2 to 8.73 HKD - CStone Pharmaceuticals growing from 0.8 to 3.89 HKD - Innovent Biologics increasing from 26.45 to 105.5 HKD [4] - The current bullish trend in Hong Kong's innovative drug sector is viewed as just the beginning, with expectations of a long-term market cycle lasting 50 years [4] Group 3: Historical Comparisons - Historical data from 2005 to 2007 shows that Hong Kong real estate stocks typically initiated their upward trends over six months before A-share stocks, with A-share stocks generally experiencing greater increases [5] - Examples include: - China Overseas Land rising from 2.29 to 21.95 HKD - Vanke increasing from 6.76 to 33.82 HKD - Deep Zhenye rising from 19.90 to 271.8 HKD [5] - The patterns observed in the real estate sector may provide insights into the potential trajectory of mainland innovative drug stocks, suggesting a possible follow-up to the Hong Kong market's performance [5]